Literature DB >> 23302910

Pfizer's first-in-class JAK inhibitor pricey for rheumatoid arthritis market.

Ken Garber.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23302910     DOI： 10.1038/nbt0113-3

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN： 1087-0156            Impact factor:   54.908


× No keyword cloud information.
  2 in total

1.  Tofacitinib or adalimumab versus placebo in rheumatoid arthritis.

Authors:  Ronald F van Vollenhoven; Roy Fleischmann; Stanley Cohen; Eun Bong Lee; Juan A García Meijide; Sylke Wagner; Sarka Forejtova; Samuel H Zwillich; David Gruben; Tamas Koncz; Gene V Wallenstein; Sriram Krishnaswami; John D Bradley; Bethanie Wilkinson
Journal:  N Engl J Med       Date:  2012-08-09       Impact factor: 91.245

2.  Pfizer's JAK inhibitor sails through phase 3 in rheumatoid arthritis.

Authors:  Ken Garber
Journal:  Nat Biotechnol       Date:  2011-06-07       Impact factor: 54.908
  2 in total
  10 in total

1.  New partner for Galapagos JAK drug.

Authors: 
Journal:  Nat Biotechnol       Date:  2016-02       Impact factor: 54.908

2.  Setback for JAK2 inhibitors.

Authors:  Mark Ratner
Journal:  Nat Biotechnol       Date:  2014-02       Impact factor: 54.908

3.  Caerulomycin A enhances transforming growth factor-β (TGF-β)-Smad3 protein signaling by suppressing interferon-γ (IFN-γ)-signal transducer and activator of transcription 1 (STAT1) protein signaling to expand regulatory T cells (Tregs).

Authors:  Rama Krishna Gurram; Weshely Kujur; Sudeep K Maurya; Javed N Agrewala
Journal:  J Biol Chem       Date:  2014-05-08       Impact factor: 5.157

4.  Influence of TYK2 in systemic sclerosis susceptibility: a new locus in the IL-12 pathway.

Authors:  Elena López-Isac; Diana Campillo-Davo; Lara Bossini-Castillo; Sandra G Guerra; Shervin Assassi; Carmen Pilar Simeón; Patricia Carreira; Norberto Ortego-Centeno; Paloma García de la Peña; Lorenzo Beretta; Alessandro Santaniello; Chiara Bellocchi; Claudio Lunardi; Gianluca Moroncini; Armando Gabrielli; Gabriela Riemekasten; Torsten Witte; Nicolas Hunzelmann; Alexander Kreuter; Jörg Hw Distler; Alexandre E Voskuyl; Jeska de Vries-Bouwstra; Ariane Herrick; Jane Worthington; Christopher P Denton; Carmen Fonseca; Timothy Rdj Radstake; Maureen D Mayes; Javier Martín
Journal:  Ann Rheum Dis       Date:  2015-09-02       Impact factor: 19.103

5.  Generation of a chemical genetic model for JAK3.

Authors:  Judit Remenyi; Rangeetha Jayaprakash Naik; Jinhua Wang; Momchil Razsolkov; Alyssa Verano; Quan Cai; Li Tan; Rachel Toth; Samantha Raggett; Carla Baillie; Ryan Traynor; C James Hastie; Nathanael S Gray; J Simon C Arthur
Journal:  Sci Rep       Date:  2021-05-12       Impact factor: 4.379

6.  TYK2 protein-coding variants protect against rheumatoid arthritis and autoimmunity, with no evidence of major pleiotropic effects on non-autoimmune complex traits.

Authors:  Dorothée Diogo; Lisa Bastarache; Katherine P Liao; Robert R Graham; Robert S Fulton; Jeffrey D Greenberg; Steve Eyre; John Bowes; Jing Cui; Annette Lee; Dimitrios A Pappas; Joel M Kremer; Anne Barton; Marieke J H Coenen; Barbara Franke; Lambertus A Kiemeney; Xavier Mariette; Corrine Richard-Miceli; Helena Canhão; João E Fonseca; Niek de Vries; Paul P Tak; J Bart A Crusius; Michael T Nurmohamed; Fina Kurreeman; Ted R Mikuls; Yukinori Okada; Eli A Stahl; David E Larson; Tracie L Deluca; Michelle O'Laughlin; Catrina C Fronick; Lucinda L Fulton; Roman Kosoy; Michael Ransom; Tushar R Bhangale; Ward Ortmann; Andrew Cagan; Vivian Gainer; Elizabeth W Karlson; Isaac Kohane; Shawn N Murphy; Javier Martin; Alexandra Zhernakova; Lars Klareskog; Leonid Padyukov; Jane Worthington; Elaine R Mardis; Michael F Seldin; Peter K Gregersen; Timothy Behrens; Soumya Raychaudhuri; Joshua C Denny; Robert M Plenge
Journal:  PLoS One       Date:  2015-04-07       Impact factor: 3.240

7.  In vivo administration of a JAK3 inhibitor during acute SIV infection leads to significant increases in viral load during chronic infection.

Authors:  Yoshiaki Takahashi; Siddappa N Byrareddy; Christina Albrecht; Markus Brameier; Lutz Walter; Ann E Mayne; Paul Dunbar; Robert Russo; Dawn M Little; Tara Villinger; Ladawan Khowawisetsut; Kovit Pattanapanyasat; Francois Villinger; Aftab A Ansari
Journal:  PLoS Pathog       Date:  2014-03-06       Impact factor: 6.823

Review 8.  Clinical utility of the oral JAK inhibitor tofacitinib in the treatment of rheumatoid arthritis.

Authors:  Maurizio Cutolo; Marianna Meroni
Journal:  J Inflamm Res       Date:  2013-11-15

Review 9.  From Science to Success? Targeting Tyrosine Kinase 2 in Spondyloarthritis and Related Chronic Inflammatory Diseases.

Authors:  Dominika Hromadová; Dirk Elewaut; Robert D Inman; Birgit Strobl; Eric Gracey
Journal:  Front Genet       Date:  2021-07-05       Impact factor: 4.599

10.  EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update.

Authors:  Josef S Smolen; Robert Landewé; Ferdinand C Breedveld; Maya Buch; Gerd Burmester; Maxime Dougados; Paul Emery; Cécile Gaujoux-Viala; Laure Gossec; Jackie Nam; Sofia Ramiro; Kevin Winthrop; Maarten de Wit; Daniel Aletaha; Neil Betteridge; Johannes W J Bijlsma; Maarten Boers; Frank Buttgereit; Bernard Combe; Maurizio Cutolo; Nemanja Damjanov; Johanna M W Hazes; Marios Kouloumas; Tore K Kvien; Xavier Mariette; Karel Pavelka; Piet L C M van Riel; Andrea Rubbert-Roth; Marieke Scholte-Voshaar; David L Scott; Tuulikki Sokka-Isler; John B Wong; Désirée van der Heijde
Journal:  Ann Rheum Dis       Date:  2013-10-25       Impact factor: 19.103
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.